Previous close | 348.75 |
Open | 352.00 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 351.00 - 352.00 |
52-week range | 215.50 - 352.00 |
Volume | |
Avg. volume | 810 |
Market cap | N/A |
Beta (5Y monthly) | 0.90 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Revenue up 4.9%, enabling market share gains despite difficulties in 20232023 operating profitability1 at an all-time high of 23.2% of revenue Up 0.4 points compared to 2022 Strong momentum expected in 2024 Expected revenue growth of 4% to 6% at constant exchange rates and scopeOperating profitability1 expected to rise by 0,5 point CONSOLIDATED FIGURES AS OF DECEMBER 31in millions of € 2023 2022restated6 2023/2022 change Revenue 1 246.9 1 216.2 +2.5% Change at constant exchange rates and scope2
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital(Article 223-16 of the General regulations of the French Financial Market Authority – Autoritédes Marchés Financiers) Quotation place: Euronext ParisCompartiment AISIN code: FR0000031577 DateTotal number of shares representing the share capitalTotal number of voting rightsFebruary, 29 20248 458 000Gross total of voting rights : 12 774 320Net total* of
Virbac announces that it has signed a definitive agreement with ORIX Corporation for the acquisition of its animal health subsidiary Sasaeah for an enterprise value of approximately €280 million. Formed through the combination of two legacy animal health providers (Fujita Pharmaceutical Co. Ltd. and Kyoto Biken Laboratories Inc.) under the stewardship of ORIX Corporation, Sasaeah generates annual revenues of about €75 million, of which 50% from vaccines. With strong footholds in Japan, Sasaeah d